Table I.
Associations between clinicopathological characteristics and high (n=470) or low (n=155) pre-treatment RDW-to-LYM% ratio in patients with upper tract urothelial carcinoma.
| RDW-to-LYM% ratio | ||||
|---|---|---|---|---|
| Variables | All patients | Low (≤0.80) | High (>0.80) | P-value |
| Mean age ± SD, years | 69.3±11.0 | 69.3±10.7 | 69.1±11.8 | |
| Median follow-up time after surgery, months | 47.8 | 51.5 | 31.1 | |
| Age, n (%) | 0.598 | |||
| ≤69 years | 295(47) | 219(47) | 76(49) | |
| >69 years | 330(53) | 251(53) | 79(51) | |
| Sex, n (%) | 0.969 | |||
| Male | 271(43) | 204(43) | 67(43) | |
| Female | 354(57) | 266(57) | 88(57) | |
| Renal function, n (%) | 0.005 | |||
| Pre-eGFR ≥60 ml/min/1.73 m2 | 253(40) | 205(44) | 48(31) | |
| Pre-eGFR <60 ml/min/1.73 m2 | 372(60) | 265(56) | 107(69) | |
| HTN or DM, n (%) | 0.300 | |||
| No | 264(42) | 193(41) | 71(46) | |
| Yes | 361(58) | 277(59) | 84(54) | |
| Hematuria, n (%) | 0.522 | |||
| No | 82(13) | 64(14) | 18(12) | |
| Yes | 543(87) | 406(86) | 137(88) | |
| Hydronephrosis, n (%) | 0.363 | |||
| No | 133(21) | 96(20) | 37(24) | |
| Yes | 492(79) | 374(80) | 118(76) | |
| Previous BC, n (%) | 0.016 | |||
| No | 533(85) | 410(87) | 123(79) | |
| Yes | 92(15) | 60(13) | 32(21) | |
| Concomitant BC, n (%) | 0.010 | |||
| No | 504(81) | 390(83) | 114(74) | |
| Yes | 121(19) | 80(17) | 41(26) | |
| Tumor location, n (%) | 0.003 | |||
| Pelvis | 284(45) | 210(45) | 74(48) | |
| Ureter | 206(33) | 170(36) | 36(23) | |
| Both | 135(22) | 90(19) | 45(29) | |
| Pathologic T stage, n (%) | <0.001 | |||
| Tis/a/1 | 229(37) | 184(39) | 45(29) | |
| T2 | 122(20) | 101(21) | 21(14) | |
| T3/4 | 274(44) | 185(39) | 89(57) | |
| Lymph node status, n (%) | <0.001 | |||
| N0 | 109(17) | 70(15) | 39(25) | |
| Nx | 478(76) | 380(81) | 98(63) | |
| N+ | 38(6) | 20(4) | 18(12) | |
| Tumor grade, n (%) | 0.290 | |||
| Low | 30(5) | 25(5) | 5(3) | |
| High | 595(95) | 445(95) | 150(97) | |
| Tumor size, n (%) | 0.045 | |||
| ≤2 cm | 172(28) | 139(30) | 33(21) | |
| >2 cm | 453(72) | 331(70) | 122(79) | |
| Lymphovascular invasion, n (%) | <0.001 | |||
| Absent | 444(71) | 351(75) | 93(60) | |
| Present | 181(29) | 119(25) | 62(40) | |
| Tumor necrosis, n (%) | 0.070 | |||
| Absent | 503(80) | 386(82) | 117(75) | |
| Present | 122(20) | 84(18) | 38(25) | |
| Adjuvant chemotherapy, n (%) | 0.968 | |||
| No | 564(90) | 424(90) | 140(90) | |
| Yes | 61(10) | 46(10) | 15(10) | |
RDW-to-LYM% ratio, red cell distribution width to lymphocyte percentage ratio; pre-eGFR, preoperative estimated glomerular filtration rate; BC, bladder cancer; HTN, hypertension; DM, diabetes mellitus.